6-methyl-(4-methylthio)furo[2,3-d]pyrimidine | 655253-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃[2,3-d]嘧啶
• 英文名称: 6-methyl-(4-methylthio)furo[2,3-d]pyrimidine
• 英文别名: 6-Methyl-4-(methylthio)furo[2,3-d]pyrimidine；6-methyl-4-methylsulfanylfuro[2,3-d]pyrimidine
• CAS: 655253-89-7
• 化学式: C₈H₈N₂OS
• 分子量: 180.23
• InChiKey: UBHBOVOSUINAFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氯-6-甲基-呋喃并[2,3-d]嘧啶 在 sodium thiomethoxide 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以90%的产率得到6-methyl-(4-methylthio)furo[2,3-d]pyrimidine
  参考文献：
  名称：

  [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
  [FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)

  摘要：

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。

  公开号：

  WO2004013141A1

文献信息

• Condensed pyridines and pyrimidines with tie2 (tek) activity
  申请人：Luke Arthur Richard William

  公开号：US20050256140A1

  公开（公告）日：2005-11-17

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR 5 ; Z is selected from N and CR 6 ; Q 1 is selected from optionally substituted aryl and heteroaryl, and the substituents R 1 to R 6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的式子（I），其中A与其连接的碳原子一起形成一个融合的5元杂环芳基环，其中该杂环芳基环含有1或2个从O，N和S中选择的杂原子，并且含有G的5元环与在式子（I）中被标记为#的桥头碳上的A形成的环在间位连接：G从O，S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂环基中选择，取代基R1到R6如文本中所定义，用于在温血动物如人中产生抗血管生成效应的制备。
• Condensed pyridines and pyrimidines with tie2 (TEK) activity
  申请人：AstraZeneca AB

  公开号：US07427616B2

  公开（公告）日：2008-09-23

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR5; Z is selected from N and CR6; Q1 is selected from optionally substituted aryl and heteroaryl, and the substituents R1 to R6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的公式（I），其中A与其连接的碳原子共同形成一个融合的五元杂环芳基环，其中所述杂环芳基环包含从O、N和S中选择的1或2个杂原子，且含有G的五元环与在公式（I）中由A形成的环在桥头碳标记#的间位相连：G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂芳基中选择，取代基R1至R6在文本中定义，用于在温血动物如人体中产生抗血管生成效应。
• CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
  申请人：Astrazeneca AB

  公开号：EP1537112A1

  公开（公告）日：2005-06-08
• US7427616B2
  申请人：——

  公开号：US7427616B2

  公开（公告）日：2008-09-23
• [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY<br/>[FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)
  申请人：ASTRAZENECA AB

  公开号：WO2004013141A1

  公开（公告）日：2004-02-12

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I); G is selected from O, S and NR5; Z is selected from N and CR6; Q1 is selected from optionally substituted aryl and heteroaryl, and the substituents R1 to R6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。